Myriad Genetics stock falls after guidance reset and weak Q2 figures

Published on 09/20/2026 at 21:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Myriad Genetics stock closed at USD 3.89 on September 18, 2026 on Nasdaq after Q2 2026 revenue of USD 190.7 million and a net loss, while analysts now see downside to an average price target near USD 3.12. The shares are down 36.7% year-to-date and sit near a USD 0.36 billion market cap.

MYGN, US62855J1043, Illustration mit AI erstellt.

Myriad Genetics Inc. (ISIN US62855J1043) stock closed at USD 3.89 on Nasdaq on September 18, 2026, down 6.04% for the day and 36.7% since the start of the year, putting the diagnostics specialist under clear pressure from weak recent results and a reset of expectations.

Q2 2026 results and guidance reset weigh on sentiment

According to Zacks, Myriad Genetics reported revenue of USD 190.7 million in its last reported quarter, Q2 2026, a decline of 10.5% compared with the same quarter a year earlier.

For that Q2 2026 period, the company posted earnings per share of minus USD 0.25, versus positive USD 0.05 a year ago, underlining how profitability has moved from a modest profit into a loss over the past twelve months, a shift that has clearly unsettled the market.

As summarized by Zacks on September 20, 2026, the Zacks Consensus Estimate for the current quarter points to a loss of USD 0.16 per share for Myriad Genetics, with the consensus having been cut by 118.2 percent over the last 30 days and the stock now carrying a Zacks Rank 5 (Strong Sell).

Analyst targets signal further downside and reflect risk

A recent overview from MarketBeat dated September 19, 2026 shows that Myriad Genetics has a consensus price target of USD 3.12, which represents about 19.8% downside from the closing price of USD 3.89 on September 18, 2026.

According to this same MarketBeat overview, the company’s average rating score stands at 1.57 based on zero strong buy ratings, zero buy ratings, four hold ratings and three sell ratings, highlighting that the analyst community overall takes a cautious to negative stance on the shares.

The same MarketBeat data indicate that Myriad Genetics stock started 2026 at USD 6.15 and has since fallen 36.7% to USD 3.89 as of September 18, 2026, a decline that closely mirrors the deterioration in earnings and the reset of guidance implied by recent estimate cuts.

Market reaction, valuation and risk profile

The weakness in fundamentals and guidance has fed directly into market valuation. As of mid-September 2026, Myriad Genetics carries a market capitalization of about USD 0.36 billion, based on combined Nasdaq and portal data compiled by CompaniesMarketCap, with that value reported for September 16, 2026.

The same CompaniesMarketCap overview shows that Myriad Genetics’ market capitalization in 2026 is down 38.88% compared with the prior year, a slump that is broadly consistent with the drop in the share price and reflects how investors have repriced the company as growth slows and losses persist.

In addition, MarketBeat’s tools classify the company’s financial health in a red zone category for at least one month, according to the TradeSmith risk flag noted in the MarketBeat stock page, underscoring that from a risk perspective, the stock is currently seen as vulnerable.

Stock level and recent price history

Per Nasdaq-based pricing reported by MarketBeat, Myriad Genetics stock closed at USD 3.89 on September 18, 2026 at 4:00 p.m. Eastern Time on its primary listing on Nasdaq, with an intraday decline of USD 0.25 or 6.04% versus the prior close.

Extended trading data on the same day show the shares at USD 3.87 as of 7:55 p.m. Eastern Time on September 18, 2026, indicating only a slight further softening after the regular session but confirming that the market has not yet found a firm floor around the USD 4.00 level.